Home » Stocks » SGEN

Seagen, Inc. (SGEN)

Stock Price: $152.55 USD 1.44 (0.95%)
Updated Mar 1, 2021 4:00 PM EST - Market closed
After-hours: $153.88 +1.33 (0.87%) Mar 1, 7:29 PM
Market Cap 27.61B
Revenue (ttm) 2.18B
Net Income (ttm) 613.67M
Shares Out 174.83M
EPS (ttm) 3.37
PE Ratio 45.27
Forward PE 909.09
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $152.55
Previous Close $151.11
Change ($) 1.44
Change (%) 0.95%
Day's Open 152.21
Day's Range 150.58 - 153.57
Day's Volume 1,294,877
52-Week Range 90.57 - 213.94

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 week ago

Seagen (SGEN) and Astellas Pharma announced completion of submissions of two sBLAs to the FDA for Padcev in patients with locally advanced or metastatic urothelial carcinoma.

PRNewsWire - 1 week ago

TOKYO and BOTHELL, Wash., Feb. 18, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq:SGEN) today announced com...

Business Wire - 1 week ago

BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced completion of subm...

Zacks Investment Research - 2 weeks ago

The European Commission approves Seagen's (SGEN) Tukysa in combination with Herceptin and Xeloda to treat adults with HER2-positive locally advanced or metastatic breast cancer.

Business Wire - 2 weeks ago

BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced primary results fr...

Business Wire - 2 weeks ago

BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced results from the s...

Zacks Investment Research - 2 weeks ago

Seagen (SGEN) surpasses estimates for earnings and revenues in the fourth quarter of 2020. The company provides revenues guidance for 2021.

Business Wire - 2 weeks ago

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced that the European Commission (EC) has granted marketing authorization for TUKYSA® (tucatinib) in combination with tra...

Zacks Investment Research - 2 weeks ago

Seattle Genetics (SGEN) delivered earnings and revenue surprises of 11.11% and 3.04%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the st...

Business Wire - 2 weeks ago

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2020. The Company also highlighted ADCETRIS® (bre...

Zacks Investment Research - 2 weeks ago

Seagen (SGEN) submits a BLA to the FDA for accelerated approval of tisotumab vedotin in patients with recurrent/metastatic cervical cancer, whose disease has progressed on or after chemotherapy.

Business Wire - 2 weeks ago

BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced the submission of a Biologics License Application (BLA) to the U...

Other stocks mentioned: GMAB
Zacks Investment Research - 2 weeks ago

Seagen (SGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

The Motley Fool - 3 weeks ago

The rumor mill took hold in late-day trading.

Seeking Alpha - 1 month ago

BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and p...

Other stocks mentioned: ANNX, ASA, BME, BMEZ, BST, BSTZ, GMAB, GNMSF, KYMR, MASI, OSH, SGTX, TSHA
The Motley Fool - 1 month ago

Revenue growth is just beginning for these companies.

Other stocks mentioned: MRNA, VERX
Business Wire - 1 month ago

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its fourth quarter and full year 2020 financial results on Thursday, February 11, 2021 after the...

GuruFocus - 2 months ago

Seagen, Inc. (SGEN) has recently been named Biotech of the Year by leading industry publication Biopharma Dive, and investors would no doubt agree. Shares of the Seattle-area firm are up nearl...

Business Wire - 2 months ago

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that management will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Monday, January 11, 202...

InvestorPlace - 2 months ago

It's a relief to know Covid-19 vaccines are on the way. But there are plenty of other great biotechs that have been overlooked in the market frenzy.

Other stocks mentioned: BNTX, CRSP, DNLI, MRTX, NVAX, ZLAB
Zacks Investment Research - 2 months ago

Seagen (SGEN) gets a positive opinion from the CHMP, recommending the approval of Tukysa for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer.

Business Wire - 2 months ago

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive op...

Business Wire - 2 months ago

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced the presentation of new data from TUKYSA (tucatinib), its HER2-positive metastatic breast cancer therapy, at the San ...

Business Wire - 2 months ago

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced multiple ADCETRIS® (brentuximab vedotin) data presentations at the 62nd American Society of Hematology (ASH) Annual M...

The Motley Fool - 3 months ago

All of these stocks are down more than 10% in the past four weeks.

Other stocks mentioned: TWTR, BYND
Business Wire - 3 months ago

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced the presentation of immuno-oncology data from its broad pipeline of therapies at the Society for Immunotherapy of Can...

Business Wire - 3 months ago

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced multiple ADCETRIS® (brentuximab vedotin) data presentations at the upcoming 62nd American Society of Hematology (ASH)...

Business Wire - 3 months ago

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) announced today that it will host a virtual R&D day for investors and analysts on Monday, November 16, 2020 beginning at 10:00 a.m. ...

Seeking Alpha - 4 months ago

Seagen have struck gold with its Merck deal, which sees billions in value creation with long-tailed asset returns. Its antibody-drug conjugate segment has seen label expansion into several key...

Zacks Investment Research - 4 months ago

Seagen's (SGEN) bottom line grows year over year in Q3 while revenues beat estimates. The company lowers the sales guidance for its lead product Adcetris.

The Motley Fool - 4 months ago

A broad market sell-off is trumping third-quarter results that outpaced analyst expectations.

Seeking Alpha - 4 months ago

Seagen's (SGEN) CEO Clay Siegall on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 months ago

Seattle Genetics (SGEN) delivered earnings and revenue surprises of 4475.00% and 166.81%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for t...

Business Wire - 4 months ago

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today reported financial results for the third quarter and nine months ended September 30, 2020. The Company also highlighted ADCETRI...

Business Wire - 4 months ago

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced the closing of a $1.0 billion equity investment by Merck in 5.0 million newly-issued shares of Seagen common stock a...

InvestorPlace - 4 months ago

Most Nasdaq stocks have seen ups and downs this year. But these seven have weathered the pandemic well and are bound to climb higher soon.

Other stocks mentioned: AAPL, CRSP, CTXS, MELI, PYPL, TSLA
Zacks Investment Research - 4 months ago

Seattle Genetics (SGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 4 months ago

Let us take a look at some drug/biotech stocks including Glaxo (GSK) and Merck (MRK) that are poised to beat on earnings for the third quarter.

Other stocks mentioned: BMY, GSK, MRK, VRTX
Zacks Investment Research - 4 months ago

Seagen (SGEN) and partner Astellas Pharma post favorable top-line results from the second cohort of the phase II EV-201 study on Padcev to treat advanced or metastatic urothelial cancer. Stock...

Business Wire - 4 months ago

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) announced today that it will report its third quarter 2020 financial results on Thursday, October 29, 2020 after the close of U.S. f...

Business Wire - 4 months ago

BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced positive topline r...

Business Wire - 4 months ago

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. changes names to Seagen Inc.

The Motley Fool - 4 months ago

Investors celebrated news of a big partnership -- and a big capital infusion.

CNBC Television - 4 months ago

Final Trades: Seattle Genetics, Greenbrier, CVS Health & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other stocks mentioned: CVS, GBX, BAH, STZ, STZ.B
The Motley Fool - 4 months ago

Prep your portfolio by buying shares of healthcare companies that can deliver revenue growth in the worst of times.

Other stocks mentioned: ABT, EXEL
Seeking Alpha - 5 months ago

Agenus Vs. Seattle Genetics Cervical Cancer Clinical Trial Results

Other stocks mentioned: AGEN
Zacks Investment Research - 5 months ago

As of late, it has definitely been a great time to be an investor in Seattle Genetics.

Business Wire - 5 months ago

BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) and Genmab A/S (Nasdaq: GMAB) today presented data from the innovaTV 204 pivotal phase 2, single-arm...

Other stocks mentioned: GMAB
Zacks Investment Research - 5 months ago

Seattle Genetics' (SGEN) phase III EV-301 study on Padcev meets the main goal of overall survival compared to chemotherapy in patients previously treated for locally advanced/metastatic urothe...

PRNewsWire - 5 months ago

TOKYO and BOTHELL, Wash., Sept. 18, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seattle Genetics, Inc. (Nasdaq:SGEN) today a...

About SGEN

Seagen, a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It als... [Read more...]

Industry
Biotechnology
CEO
Dr. Clay B. Siegall
Employees
2,092
Stock Exchange
NASDAQ
Ticker Symbol
SGEN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 19 analysts, the average rating for Seagen stock is "Buy." The 12-month stock price forecast is 195.20, which is an increase of 27.96% from the latest price.

Price Target
$195.20
(27.96% upside)
Analyst Consensus: Buy